12 LHRH analogues in the management of uterine fibroids, premenstrual syndrome and breast malignancies

Andersch, 1986, Premenstrual complaints. 1. Prevalence of premenstrual symptoms in a Swedish urban population, Journal of Psychosomatic Obstetrics and Gynecology, 5, 39, 10.3109/01674828609016741 Backstrom, 1986, Buserelin and premenstrual syndrome, British Journal of Clinical Practice, 41, 49 Bancroft, 1987, The use of an LHRH agonist, buserelin, in the long term management of premenstrual syndromes, Clinical Endocrinology, 27, 171, 10.1111/j.1365-2265.1987.tb01142.x Bergquist, 1982, Intranasal LHRH agonist treatment for inhibition of ovulation in women: clinical aspects, Clinical Endocrinology, 17, 91, 10.1111/j.1365-2265.1982.tb02638.x Blankenstein, 1985, Direct inhibitory effect of a luteinizing-hormone releasing hormone agonist on MCF-7 human breast cancer cells, European Journal of Cancer and Clinical Oncology, 21, 1493, 10.1016/0277-5379(85)90244-5 Bonadonna, 1976, Combination chemotherapy as an adjuvant treatment in operable breast cancer, New England Journal of Medicine, 294, 405, 10.1056/NEJM197602192940801 Bonney, 1931, The technique and results of myomectomy, Lancet, i, 171, 10.1016/S0140-6736(00)40479-4 Breast Cancer Trials Committee, 1987, Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial, Lancet, ii, 171 Brenner, 1985, Ovulation inhibition with nafarelin acetate nasal administration for 6 months, Contraception, 32, 531, 10.1016/S0010-7824(85)80001-9 Buttram, 1981, Uterine leiomyomata: etiology, symptomatology and management, Fertility and Sterility, 36, 433, 10.1016/S0015-0282(16)45789-4 Chang, 1983, Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist, Journal of Clinical Endocrinology and Metabolism, 56, 897, 10.1210/jcem-56-5-897 Cochrane, 1974, Ultrasound diagnosis of gynecologic pelvic masses, Radiology, 110, 649, 10.1148/110.3.649 Coddington, 1986, Long-acting gonadotrophin hormone-releasing hormone analog used to treat uteri, Fertility and Sterility, 45, 624, 10.1016/S0015-0282(16)49332-5 Coppen, 1963, Menstruation and personality, British Journal of Psychiatry, 109, 711, 10.1192/bjp.109.463.711 Dalton, 1977 Dennerstein, 1984, Premenstrual tension—hormone profiles, Journal of Psychosomatic Obstetrics and Gynecology, 3, 37, 10.3109/01674828409023851 Dickson, 1986, Induction of epidermal growth factor-related polypeptides by 17B-oestradiol in MCF-7 human breast cancer cells, Endocrinology, 118, 138, 10.1210/endo-118-1-138 Eidne, 1987, Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists, Journal of Clinical Endocrinology and Metabolism, 64, 425, 10.1210/jcem-64-3-425 Emons, 1988, The use of GnRH analogues in ovarian cancer, Gynecological Endocrinology, 2, 38 Filicori, 1983, A conservative approach to the management of uterine leiomyomata: pituitary desensitisation by a luteinizing hormone-releasing hormone analogue, American Journal of Obstetrics and Gynecology, 147, 726, 10.1016/0002-9378(83)90463-5 Fisher, 1975, L-phenylalanine mustard (L-Pam) in the management of primary breast cancer. A report of early findings, New England Journal of Medicine, 292, 117, 10.1056/NEJM197501162920301 Fraser, 1987, Clinical applications of LHRH analogues, Clinical Endocrinology and Metabolism, 1, 43 Friedman, 1987, Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist, Fertility and Sterility, 48, 560, 10.1016/S0015-0282(16)59464-3 Friedman, 1988, A randomised double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxy-progesterone acetate in the treatment of leiomyomata uteri, Gynecological Endocrinology, 2, 90 Goldzieher, 1966, Induction of degenerative changes in uterine myomas by high dose progestin therapy, American Journal of Obstetrics and Gynecology, 96, 1078, 10.1016/0002-9378(66)90516-3 Groom, 1976, Effect of the antioestrogen tamoxifen on plasma levels of luteinizing hormone, follicle stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women, Journal of Endocrinology, 70, 421, 10.1677/joe.0.0700421 Hannigan, 1979, Uterine leiomyosarcoma: a review of prognostic clinical and pathological features, American Journal of Obstetrics and Gynecology, 134, 557, 10.1016/0002-9378(79)90841-X Hardt, 1983, Sustained gonadal suppression in fertile women with the LHRH agonist buserelin, Clinical Endocrinology, 19, 613, 10.1111/j.1365-2265.1983.tb00039.x Harvey, 1981, Phase II study of a gonadotropin-releasing hormone analogue (Leuprolide) in postmenopausal advanced breast cancer, 22, 444 Hawkins, 1985, Receptors in the management of breast cancer, British Journal of Hospital Medicine, 34, 160 Healy, 1986, Towards removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase, Journal of Clinical Endocrinology and Metabolism, 63, 619, 10.1210/jcem-63-3-619 Henderson, 1980, Cancer of the breast. The past decade, New England Journal of Medicine, 302, 17, 10.1056/NEJM198001033020104 Henderson, 1980, Cancer of the breast. The past decade, New England Journal of Medicine, 302, 78, 10.1056/NEJM198001103020203 Herzberg, 1970, Changes in psychological symptoms in women taking oral contraceptives, British Journal of Psychiatry, 116, 161, 10.1192/bjp.116.531.161 Hofman, 1984, Binding sites for epidermal growth factor in human uterine tissue and leiomyomas, Journal of Clinical Endocrinology and Metabolism, 58, 880, 10.1210/jcem-58-5-880 Howell, 1984, Steroid-hormone receptors and survival after first relapse in breast cancer, Lancet, i, 588, 10.1016/S0140-6736(84)90995-4 Hricak, 1985, Gynecologic masses: value of magnetic resonance imaging, American Journal of Obstetrics and Gynecology, 153, 31, 10.1016/0002-9378(85)90585-X Hutchison, 1987, Sustained release formulations of LHRH analogues, 409 Ingle, 1984, Additive hormonal therapy in women with advanced breast cancer, Cancer, 53, 766, 10.1002/1097-0142(19840201)53:3+<766::AID-CNCR2820531327>3.0.CO;2-H Kaufmann, 1988, Zoladex as GnRH-agonist in premenopausal patients with metastatic breast cancer, Gynecological Endocrinology, 2, 133 Kenigsberg, 1986, Ovulation inhibition by administration of weekly gonadotropin-releasing hormone antagonist, Journal of Clinical Endocrinology and Metabolism, 62, 734, 10.1210/jcem-62-4-734 Klijn, 1984, Anti-tumor and endocrine effects of chronic LHRH agonist treatment (buserelin) with or without tamoxifen in premenopausal metastatic breast cancer, Breast Cancer Research and Treatment, 4, 209, 10.1007/BF01806487 Klijn, 1985, LHRH-agonist treatment in clinical and experimental human breast cancer, Journal of Steroid Biochemistry, 23, 867, 10.1016/S0022-4731(85)80029-7 Koenders, 1980, Quality control of estrogen receptor assays in the Netherlands, Breast Cancer Research and Treatment, 3, 255, 10.1007/BF01806699 Kutner, 1972, History of depression as a risk factor for depression with oral contraceptives and discontinuance, Journal of Nervous and Mental Diseases, 155, 163, 10.1097/00005053-197209000-00002 Lawson, 1977, Diagnosis of gynecologic pelvic masses by gray scale ultrasonography: analysis of specificity and accuracy, American Journal of Roentgenology, 128, 1003, 10.2214/ajr.128.6.1003 Lemay, 1984, Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (buserelin) as a new therapeutic approach for endometriosis, Fertility and Sterility, 41, 863, 10.1016/S0015-0282(16)47899-4 Lindsay, 1976, Long term prevention of postmenopausal osteoporosis by oestrogen, Lancet, i, 1038, 10.1016/S0140-6736(76)92217-0 Luder, 1984, Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long acting analog of luteinizing hormone releasing hormone, Journal of Endocrinology and Metabolism, 58, 966, 10.1210/jcem-58-6-966 Lumsden, 1987, Goserelin therapy before surgery for uterine fibroids, Lancet, i, 36, 10.1016/S0140-6736(87)90718-5 Lumsden, 1988, Change in receptors for oestradiol, progesterone and EGF in uterine fibromyomata following treatment with goserelin (Zoladex ICI), Gynecological Endocrinology, 2, 27 Lumsden, 1988, The binding of EGF to the human uterus and leiomyomata in women rendered hypo-oestrogenic by continuous administration of a LHRH agonist, British Journal of Obstetrics and Gynaecology, 10.1111/j.1471-0528.1988.tb06821.x Maheux, 1985, Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study, American Journal of Obstetrics and Gynecology, 152, 1034, 10.1016/0002-9378(85)90554-X Manni, 1986, Treatment of breast cancer with gonadotropin-releasing hormone, Endocrine Reviews, 7, 89, 10.1210/edrv-7-1-89 Mathe, 1986, Phase II trial of D-Trp6-LH-RH in advanced breast cancer, European Journal of Cancer and Clinical Oncology, 22, 723, 10.1016/0277-5379(86)90203-8 Matta, 1987, Hypogonadism induced by luteinizing hormone releasing hormone analogues: effects on bone density in premenopausal women, British Medical Journal, 294, 1523, 10.1136/bmj.294.6586.1523 Miller, 1985, Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist, Nature, 313, 231, 10.1038/313231a0 Muse, 1984, The premenstrual syndrome: effects of ‘medical oophorectomy’, New England Journal of Medicine, 311, 1345, 10.1056/NEJM198411223112104 Parmar, 1988, Response to D-Trp-6-luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer, British Medical Journal, 296, 1229, 10.1136/bmj.296.6631.1229 Perl, 1987, Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone, Fertility and Sterility, 48, 383, 10.1016/S0015-0282(16)59403-5 Plowman, 1986, Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630, British Journal of Cancer, 54, 903, 10.1038/bjc.1986.260 Priestman, 1978, Treatment and survival in advanced breast cancer, British Medical Journal, ii, 1673, 10.1136/bmj.2.6153.1673 Ravdin, 1970, Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast cancer, Surgery, Gynecology and Obstetrics, 131, 1055 Robertson, 1988, GnRH analogues in breast cancer, Gynecological Endocrinology, 2, 50 Roger, 1986, Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules, Journal of Clinical Endocrinology and Metabolism, 62, 670, 10.1210/jcem-62-4-670 Rubin, 1942, Progress in myomectomy: surgical measures and diagnostic aids favoring lower morbidity and mortality, American Journal of Obstetrics and Gynecology, 44, 196, 10.1016/S0002-9378(42)90588-X Rubinow, 1984, Prospective assessment of menstrually related mood disorders, American Journal of Psychiatry, 141, 684, 10.1176/ajp.141.5.684 Sainsbury, 1985, Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer, Lancet, i, 364, 10.1016/S0140-6736(85)91385-6 Sandow, 1983, Clinical applications of LHRH and its analogues, Clinical Endocrinology, 18, 571, 10.1111/j.1365-2265.1983.tb00595.x Santen, 1974, Successful medical adrenalectomy with aminoglutethimide: role of altered drug metabolism, Journal of the American Medical Association, 230, 1661, 10.1001/jama.1974.03240120029015 Santen, 1986, Gonadotropin releasing hormone (GnRH) analogs in the treatment of breast and prostatic carcinoma, Breast Cancer Research and Treatment, 7, 129, 10.1007/BF01806244 Schally, 1987, Use of luteinizing hormone releasing hormone analogs in the treatment of hormone-dependent tumors, 5, 389 Schmidt-Gollwitzer, 1981, Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?, Contraception, 23, 187, 10.1016/0010-7824(81)90104-9 Scottish Cancer Registration Scheme, 1984, Cancer Registration Statistics, Scotland 1971–80 Silbergeld, 1971, The menstrual cycle: a double blind study of symptoms, moods and behaviour and biochemical variables using enovid and placebo, Psychosomatic Medicine, 33, 411, 10.1097/00006842-197109000-00003 Soules, 1982, Leiomyomas: steroid receptor content. Variation within normal menstrual cycles, American Journal of Obstetrics and Gynecology, 143, 6, 10.1016/0002-9378(82)90676-7 Stewart, 1980, The tamoxifen trial—a double blind comparison with stilboestrol in post-menopausal women with advanced breast cancer, European Journal of Cancer and Clinical Oncology, 83 Sutherland, 1965, A critical analysis of the premenstrual tension syndrome, Lancet, i, 1180, 10.1016/S0140-6736(65)92718-2 Van Leusden, 1986, Rapid reduction of uterine myomas after short-term treatment with microencapsulated D-Trp6-LHRH, Lancet, ii, 1213, 10.1016/S0140-6736(86)92215-4 Vickery, 1986, Comparison of the potential for therapeutic utilities with gonadotropin-releasing hormone agonists and antagonists, Endocrine Reviews, 7, 115, 10.1210/edrv-7-1-115 Walker, 1986, Preliminary endocrinological evaluation of a sustained release formulation of the LH-releasing hormone agonist D-ser(But)6 Azgly10 LHRH in premenopausal women with advanced breast cancer, Journal of Endocrinology, 111, 349, 10.1677/joe.0.1110349 Walsh, 1979, Gray-scale ultrasound in 204 proven gynaecological masses: accuracy and specific diagnostic criteria, Radiology, 130, 391, 10.1148/130.2.391 Wander, 1988, Zoladex—a synthetic GnRH analogue in the treatment of pre and postmenopausal advanced breast cancer, Gynecological Endocrinology, 2, 137 West, 1988, Zoladex depot (goserelin) in the assessment and management of premenstrual problems—a pilot study, Gynecological Endocrinology, 2, 182 West, 1987, Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue, Clinical Endocrinology, 26, 213, 10.1111/j.1365-2265.1987.tb00779.x West, 1987, Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot, Fertility and Sterility, 48, 45, 10.1016/S0015-0282(16)59288-7 Williams, 1986, The use of an LHRH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer, British Journal of Cancer, 53, 629, 10.1038/bjc.1986.106 Wilson, 1980, Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues, Obstetrics and Gynecology, 55, 20